Shanghai Fosun Pharmaceutical (02196): Hydrochloride Dobutamine Injection Approved for Registration
Fosun Pharmaceutical (02196) announced that its holding subsidiary Shanghai ZhaoHui Pharmaceutical Co., Ltd. has recently received approval from the National Medical Products Administration for the drug registration application of dopamine hydrochloride injection. The approved indication is for the treatment of heart failure caused by decreased myocardial contractility in organic heart disease, including low-output syndrome following cardiac surgery, as a short-term supportive therapy.
Shanghai Fosun Pharmaceutical (02196) announced that its holding subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has recently obtained approval from the National Medical Products Administration for the drug registration application of Dopamine Hydrochloride Injection. The approved indication is for the treatment of heart failure caused by decreased myocardial contractility in organic heart disease, including low output syndrome resulting from open-heart surgery, as a short-term supportive therapy.
Related Articles
"Grand Theft Auto 6" is gearing up for release, and Take-Two's (TTWO.US) earnings report shows mixed results: pre-orders exceed expectations, but losses are widening.
CHINA RE(01508): He Xingda's qualifications for the position have been approved by the National Financial Supervision and Administration Bureau.
CCID CONSULTING (02176) issued a profit warning, expecting a mid-term after-tax profit of approximately 4.299 million to 8.597 million yuan, a year-on-year decrease of about 80% to 90%.
"Grand Theft Auto 6" is gearing up for release, and Take-Two's (TTWO.US) earnings report shows mixed results: pre-orders exceed expectations, but losses are widening.
CHINA RE(01508): He Xingda's qualifications for the position have been approved by the National Financial Supervision and Administration Bureau.
CCID CONSULTING (02176) issued a profit warning, expecting a mid-term after-tax profit of approximately 4.299 million to 8.597 million yuan, a year-on-year decrease of about 80% to 90%.
RECOMMEND
